InvestorsHub Logo
Followers 32
Posts 4414
Boards Moderated 0
Alias Born 09/15/2009

Re: None

Thursday, 04/13/2023 11:10:22 AM

Thursday, April 13, 2023 11:10:22 AM

Post# of 265

Investment analysts at Cantor Fitzgerald started coverage on shares of CRISPR Therapeutics (NASDAQ:CRSP - Get Rating) in a research note issued to investors on Thursday, The Fly reports. The brokerage set an "overweight" rating and a $72.00 price target on the stock. Cantor Fitzgerald's price target suggests a potential upside of 65.63% from the company's current price.



https://www.marketbeat.com/instant-alerts/nasdaq-crsp-a-buy-or-sell-right-now-2023-04-13/

"I like long walks, especially when they are taken by people who annoy me"

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CRSP News